33 results about "Transmembrane peptide" patented technology

The invention discloses a fusion protein TAT (transactivator of transcription)-OCT4 (octamer-binding transcription factor 4), and a coding gene and application thereof. The fusion protein provided by the invention comprises a TAT transmembrane peptide and a cell reprogramming correlation factor combined with an amino end or carboxyl end of the TAT transmembrane peptide. After the fusion protein-TAT OCT4 is used for treating HAFs (human aortic fibroblasts), the proliferation of the fibroblasts is promoted, and the enhancement of the expression level of the cyclins in the fibroblasts is promoted. The TAT transmembrane peptide transported nuclei transcription factor protein can be used as a cell reprogramming method, and can have important application prospects in cell induction and clinic.

The invention belongs to the field of genetically engineered drugs and provides a mutant protein MuR5S4TR of TRAIL, and a preparation method and use thereof. The 2-10th bits of an N-terminal amino acid sequence of the mutant protein are composed of a transmembrane peptide sequence RRRRR (R5) and a binding sequence AVPI of an apoptosis inhibitor XIAP, and the 11-169th bits are TRAIL protein peptide segments (123-281aa). The specific sequence is shown in SEQ ID NO:2.

The invention belongs to the technical field of biological engineering, and particularly relates to application of EGFP-CTA2-TAT fusion protein to preparation of a fluorescent probe. A TAT part contained in the structure of the EGFP-CTA2-TAT fusion protein is transmembrane peptide which can help a designed fluorescent probe to run through a cell membrane into the interior of a cell; a CTA2 part contains an endoplasmic reticulum positioning sequence KDEL which can achieve targeted positioning of an endoplasmic reticulum in the cell; the fusion protein can achieve real-time microscopic tracing detection of the endoplasmic reticulum in a living cell and the corresponding physiological change thereof ultimately by exciting EGFP to emit green fluorescence. Compared with an ordinary endoplasmicreticulum staining agent, the fusion protein has the characteristics of good biocompatibility, safety, non-toxicity and higher targeting performance and detection sensitivity.

The invention relates to a film-through polypeptide modified virus imitation gene carrier system in the field of biology technology. It adopts nanometer particle which is formed by high molecular material with film-through polypeptide modified kation to prepare for the virus imitation gene carrier system. It uses the mode of admixing the virus imitation surface and the polypeptide modified non-virus carrier and simulating the virus to enters into the cell to improve the gene transmitting effect.

The invention discloses a ternary gene delivery system based on cell-penetrating peptide and applications of the ternary gene delivery system. The ternary gene delivery system based on the cell-penetrating peptide is prepared by adopting the following method: multifunctional polypeptide REDV-G-TAT-G-NLG-C is connected to eight active sites of octa ammonium POSS (polyhedral oligomeric silsesquioxane) through orthopyridyl disulfide-PEG-NHS ester, and thus a star polymer is formed; the star polymer with positive charges and a gene with negative electricity are bonded through electrostatic interaction, and thus a binary gene delivery system with negative electricity on the surface is formed; a polypeptide sequence rich in histidine and the binary gene delivery system are bonded through electrostatic interaction, and thus the ternary gene delivery system is formed. The ternary gene delivery system based on cell-penetrating peptide provided by the invention has targeting ability for endothelial cells, and has the functions of cell-penetrating peptide, histidine and nuclear localization signals, so that carried genes can efficiently enter cells, the escape from endosome is effectively carried out, the entering of the genes into the cell nucleus is realized, and finally, the gene delivery effect is greatly improved.

The present invention provides a tandem penetrating peptide modified tumor targeting and tumor penetrating nano drug delivery system that simultaneously recognizes integrin receptors and transmembrane protein receptors. The tandem penetrating peptide is mainly a DGR polypeptide. The fragment is formed by covalently connecting to the C-terminus of the penetrating peptide polyarginine, and the polypeptide can not only selectively recognize receptors highly expressed on the surface of two types of tumor cells, but also efficiently mediate into cells. The nano-drug delivery system is mainly composed of nano-carriers, drugs and lipid-polyethylene glycol-tandem transmembrane peptide ligand chimeras, and is a potential tumor-targeted therapy carrier.

The invention provides a high-flux prey antagonist screening method based on membrane binding protein and fluorescence complementation, relates to the field of gene engineering, and concretely discloses a novel method for screening a receptor antagonist and application thereof. According to the method, a ligand existing outside a cell and a receptor are expressed to the cytomembrane through a signal peptide fusion expression strategy; a ligand structural domain generating mutual action with the receptor is enabled to be remained at the outer side of the cytomembrane; the ligand is coupled with intracellular effect proteins through transmembrane peptide; the ligand and the receptor take mutual effects at the outer side of the cytomembrane, or the effect proteins coupled in the cells are antagonized; and the effect is converted into a macroscopical biological effect, so that the method is provided for the screening of the secretion type ligand and receptor antagonists.

The invention belongs to the technical field of bioengineering, and in particular relates to an EGF-like protein, a construction method thereof, a chimeric protein, a preparation method and application thereof. The invention provides an EGF-like protein, and the EGF-like protein is EGF‑CTA 2 ‑TAT protein, EGF‑CTA 2 The nucleotide sequence of the -TAT protein is shown in SEQ ID NO:1. EGF-CTA of the present invention 2 ‑TAT protein is chimerized with EGF protein with repair function, membrane-penetrating peptide TAT to assist transdermal absorption, and cholera toxin A2 subunit (CTA) with the ability to penetrate the cell membrane 2 ), the cell activity test results showed that EGF‑CTA 2 ‑TAT protein has obvious growth-promoting effect on BALB / c 3T3 cell line and has biological activity.

The invention provides a method of handling a hydrophobic agent, which method comprises (a) combining in an aqueous solution (i) a hydrophobic agent and (ii) an isolated peptide that is a structural analog of a transmembrane domain of an integral membrane protein, wherein one terminus of the peptide has one or more negatively charged residues, and (b) allowing the peptide to self-assemble into nanoparticles, wherein the nanoparticles comprise the hydrophobic agent.

The invention discloses a preparation method of an RGD peptide and penetrating peptide R8 co-modified ergosterol and cis-platinum active drug-loading liposome. The method comprises the main steps of ergosterol liposome preparation, ammonium chloride gradient formation, drug loading and co-modification. The method is simple in technology and easy to carry out, and the encapsulation rate of a drug is high; ergosterol is adopted to partially replace cis-platinum to exert efficacy, an ergosterol and cis-platinum active drug-loading liposome is obtained, the effect of resisting a lung cancer is guaranteed, the toxic and side effects of the drug are significantly reduced, and damage to human bodies is small; meanwhile, the RGD peptide and the penetrating peptide R8 serve as target heads, the targeting property is good, and the drug exertion effect is good.

The invention relates to anti-viral protein. The anti-viral protein is characterized in that the anti-viral protein is fusion protein and comprises a transmembrane peptide structural domain and a tandem body which is formed through at least two cytosine deaminase structural domains originated from an APOBEC family, a transmembrane peptide structural domain and various cytosine deaminase structural domains. The transmembrane peptide structural domain in the anti-viral protein provided by the invention ensures the anti-viral protein to have the transmembrane capability and to freely shuttle among cells and enters the cells in a non-receptor and non-energy dependent way; the cytosine deaminase structural domains originated from the APOBEC family ensures that the anti-viral protein can effectively inhibit the reproduction of human immunodeficiency virus and / or hepatitis B virus after entering cells; because the non-essential sequences in the APOBEC family protein molecules are removed, not only the antiviral activity of the APOBEC family protein molecules is preserved, but also the immunogenicity of the anti-viral protein is reduced, and the transmembrane efficiency of the anti-viralprotein is enhanced.

The invention discloses a transmembrane peptide-mediated antisense antibacterial agent which comprises popliteal lymph node assay (PLNA) 787; and the PLNA 787 is formed by connecting transmembrane peptide (KFF) 3K and LNA 787 by cysteine-(4-(N-maleimide methyl)-1- cyclohexidine actidione)-hexane and is prepared by a solid phase synthesis method. The transmembrane peptide-mediated antisense antibacterial agent takes bacteria curing gene as a target spot, has the advantages of being high in specificity, efficient, low in toxicity, safe and the like, has remarkable inhibition effect on the growth of drug-resistant bacteria, and especially has remarkable antagonism on the growth of methicillin-resistant staphylococcus aureus.

The invention discloses a fusion protein TAT (transactivator of transcription)-OCT4 (octamer-binding transcription factor 4), and a coding gene and application thereof. The fusion protein provided by the invention comprises a TAT transmembrane peptide and a cell reprogramming correlation factor combined with an amino end or carboxyl end of the TAT transmembrane peptide. After the fusion protein-TAT OCT4 is used for treating HAFs (human aortic fibroblasts), the proliferation of the fibroblasts is promoted, and the enhancement of the expression level of the cyclins in the fibroblasts is promoted. The TAT transmembrane peptide transported nuclei transcription factor protein can be used as a cell reprogramming method, and can have important application prospects in cell induction and clinic.

The disclosure provides fusion proteins containing N-terminal signal peptides fused to immunogenic polypeptides. The immunogenic polypeptides may be from viruses, bacteria, or fungi. The disclosure also provides elevated expression of the immunogenic polypeptides using the N-terminal signal peptide. The N-terminal signal peptides enhance synthesis of the protein, particularly where the protein is neither a secretory nor a transmembrane peptide. The fusion proteins may be used to diagnose disease and to induce immune responses.